Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Oncology: State-of-the-Art Research in Austria
share announcement

Oncology: State-of-the-Art Research in Austria

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 4865

Special Issue Editors

Dr. Bahil Ghanim

E-Mail Website
Guest Editor
1. Karl Landsteiner University of Health Sciences, Dr. Karl-Dorrek-Straße 30, 3500 Krems, Austria
2. Department of General and Thoracic Surgery, University Hospital Krems, Mitterweg 10, 3500 Krems, Austria
Interests: thoracic surgery; solitary fibrous tumor; mesothelioma; lung cancer; orphan disease biomarker
Special Issues, Collections and Topics in MDPI journals
Dr. Mir Alireza Hoda

E-Mail Website
Guest Editor
Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University Vienna, 1090 Vienna, Austria
Interests: thoracic oncology; minimal invasive and robotic oncologic surgery interventional bronchoscopy; lung cancer ; pleural mesothelioma; lung metastasis; cancer staging; cancer biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer remains one of the leading causes of death worldwide. Austrian scientists were among the pioneers in cancer research, and today, the scientific output of our small country is internationally acknowledged. Furthermore, the clinical outcome of cancer patients in our country is among the best worldwide, and thus Austrian clinicians and scientists can look back on a great history and forward to a promising future. In the present Special Issue, we want to focus on modern Austrian cancer research in times of personalized and multimodal medicine. Nationwide and international collaborations will be our focus. All types of research, from basic to translational to clinical, as well as relevant review articles summarizing state-of-the-art knowledge, are welcome for submission. The full spectrum of cancer research and malignant diseases will be considered for publication. Also, historic articles looking back to the past of Austrian cancer research are welcome for submission. This Special Issue provides a platform to present the high quality of research and standard of care for the Austrian cancer research community.

Dr. Bahil Ghanim
Dr. Mir Alireza Hoda
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncology
  • cancer
  • research
  • tumor
  • Austria

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1096 KiB  
Article
Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration
by Gerd Jomrich, Dagmar Kollmann, Winny Yan, Daniel Winkler, Matthias Paireder, Lisa Gensthaler, Hannah Christina Puhr, Aysegül Ilhan-Mutlu, Reza Asari and Sebastian F. Schoppmann
Cancers 2024, 16(21), 3624; https://doi.org/10.3390/cancers16213624 - 27 Oct 2024
Viewed by 2647
Abstract
FGF8, ALK, and EML4 have been identified as promising biomarkers in a number of malignancies. The aim of this study was to examine the prognostic role of FGF8, ALK, and EML4 in esophageal squamous cell carcinoma (ESCC). Methods: Consecutive patients with ESCC who [...] Read more.
FGF8, ALK, and EML4 have been identified as promising biomarkers in a number of malignancies. The aim of this study was to examine the prognostic role of FGF8, ALK, and EML4 in esophageal squamous cell carcinoma (ESCC). Methods: Consecutive patients with ESCC who underwent upfront resection were included in this study. ALK and EML4 gene status was evaluated by fluorescence in situ hybridization (FISH) using a triple-color break-apart single-fusion probe and a probe against 2p11. FGF8, ALK, and EML4 protein expression was determined by immunohistochemistry. Results: A total of 122 patients were included in this study. Multivariate analysis revealed that FGF8 overexpression is an independent negative prognostic factor for patients’ overall survival (OS) (p = 0.04). Furthermore, a significant correlation between the expression of FGF8, and ALK (p = 0.04) and EML4 (p = 0.01) alteration was found. Conclusions: FGF8 overexpression is an adverse independent prognostic factor in patients with upfront resected ESCC. Furthermore, FGF8 expression significantly correlates with ALK and EML4 amplification and may therefore qualify as a future therapeutic target. Full article
(This article belongs to the Special Issue Oncology: State-of-the-Art Research in Austria)
►▼ Show Figures

Figure 1

20 pages, 2539 KiB  
Article
Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study
by Maximilian Hochmair, Angelika Terbuch, David Lang, Christian Trockenbacher, Florian Augustin, Bahil Ghanim, Dominik Maurer, Hossein Taghizadeh, Christoph Kamhuber, Robert Wurm, Jörg Lindenmann, Petra Braz, Tatjana Bundalo, Merjem Begic, Johanna Bauer, Patrick Reimann, Nino Müser, Florian Huemer, Verena Schlintl, Daniela Bianconi, Bernhard Baumgartner, Peter Schenk, Markus Rauter and Konrad Hötzeneckeradd Show full author list remove Hide full author list
Cancers 2024, 16(14), 2586; https://doi.org/10.3390/cancers16142586 - 19 Jul 2024
Viewed by 1874
Abstract
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018–December 2021 at 16 leading hospital institutions in Austria, excluding patients enrolled in clinical trials. In total, 319 patients [...] Read more.
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018–December 2021 at 16 leading hospital institutions in Austria, excluding patients enrolled in clinical trials. In total, 319 patients were enrolled at a planned ~1:1:1 ratio across StI:II:III. Most tested biomarkers were programmed death ligand 1 (PD-L1; 58% expressing), Kirsten rat sarcoma virus (KRAS; 22% positive), and epidermal growth factor receptor (EGFR; 18% positive). Of 115/98/106 StI/II/III patients, 82%/85%/36% underwent surgery, followed by systemic therapy in 9%/45%/47% of those [mostly chemotherapy (ChT)]. Unresected treated StIII patients received ChT + radiotherapy [43%; followed by immune checkpoint inhibitors (ICIs) in 39% of those], ICI ± ChT (35%), and ChT-alone/radiotherapy-alone (22%). Treatment was initiated a median (interquartile range) of 24 (7–39) days after histological confirmation, and 55 (38–81) days after first medical visit. Based on exploratory analyses of all patients newly diagnosed with any stage NSCLC during 2018–2021 at 14 of the sites (N = 7846), 22%/10%/25%/43% had StI/II/III/IV. The total number was not significantly different between pre-COVID-19 (2018–2019) and study-specific COVID-19 (2020–2021) periods, while StI proportion increased (21% vs. 23%; p = 0.012). Small differences were noted in treatments. In conclusion, treatments were aligned with guideline recommendations at a time which preceded the era of ICIs and targeted therapies in the (neo)adjuvant setting. Full article
(This article belongs to the Special Issue Oncology: State-of-the-Art Research in Austria)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop